Epidemiological Study of Inflammatory Myopathies in a French Region
NCT ID: NCT02881450
Last Updated: 2019-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
117 participants
OBSERVATIONAL
2012-01-31
2019-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy
NCT02880527
Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory Myopathies
NCT04917705
Follow-up of Patients With Inflammatory Myopathies Associated With a Biobank
NCT05454527
Adult and Juvenile Myositis
NCT00017914
Metabolomic Exploration of Dysregulated Lipid Metabolism in MFN2-related CMT2A (MetaDLM_CMT2A)
NCT04881201
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The old classifications, still currently used, highlight this heterogeneity. Therefore Troyanov and coll. and Hoogendijk and coll. have each recently proposed a classification based on clinical and serological - and immuno- histological examination.
The pathogenesis and prognosis of MIs is very different depending on the entity in question.
Knowledge of the descriptive epidemiology of MIs is very limited. In fact no epidemiological work using criteria consensual classification is actually started.
We propose an epidemiological study of MIs. The main objective of the study is to determine the prevalence of MIs in Alsace at 1stJanuary 2012 by means of a "capture- recapture" study using several independent sources of case identification. The secondary objectives of the study are:
* estimating the geographical distribution of the disease in the Alsace region and / or Auvergne
* demographic description of patients : age, sex, residence , occupation
* description of the disease: patient age at diagnosis, disease classification , main clinical manifestations and complications
* Identification of paraneoplastic forms will be for the Alsace region by crossing with Alsatian cancer registries. These records will be interviewed to identify cases of MIs associated with cancers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meeting the Hoogendijk, Troyanov and Griggs classification criteria
* Alive at 1st January 2012- Domiciled in Alsace (Bas-Rhin or Haut-Rhin counties of France)
Exclusion Criteria
* All patient dead and/or non-domiciled in Alsace at 1st January 2012
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean SIBILIA, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Strasbourg, France
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4963
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.